Published On: Sun, Sep 11th, 2016

Johnson & Johnson’s (JNJ) Buy Rating Reiterated at Leerink Swann

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reaffirmed by equities researchers at Leerink Swann in a research report issued to clients and investors on Sunday.
A number of other research analysts have also recently issued reports on JNJ. BTIG Research restated a “hold” rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Morgan Stanley reiterated a “hold” rating on shares of Johnson & Johnson in a report on Thursday, May 19th. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, May 18th. Credit Suisse Group AG reiterated a “hold” rating and issued a $112.00 price target on shares of Johnson & Johnson in a report on Thursday, May 19th. Finally, Deutsche Bank AG reiterated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, May 19th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $119.53.
Johnson & Johnson (NYSE:JNJ) opened at 118.23 on Friday. The company has a 50-day moving average of $121.80 and a 200-day moving average of $115.37. The firm has a market capitalization of $323.46 billion, a price-to-earnings ratio of 22.03 and a beta of 0.61. Johnson & Johnson has a 1-year low of $89.90 and a 1-year high of $126.07.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/11/johnson-johnsons-jnj-buy-rating-reiterated-at-leerink-swann.html

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. On average, equities analysts predict that Johnson & Johnson will post $6.69 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, August 19th. Shareholders of record on Friday, August 5th were given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 0.98%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.15%.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
Other hedge funds have recently bought and sold shares of the company. Stratford Consulting LLC raised its stake in Johnson & Johnson by 0.6% in the second quarter. Stratford Consulting LLC now owns 3,201 shares of the company’s stock valued at $388,000 after buying an additional 18 shares during the period. Gateway Advisory LLC increased its position in Johnson & Johnson by 0.5% in the first quarter. Gateway Advisory LLC now owns 4,215 shares of the company’s stock valued at $456,000 after buying an additional 23 shares in the last quarter. Bollard Group LLC increased its position in Johnson & Johnson by 0.7% in the second quarter. Bollard Group LLC now owns 3,895 shares of the company’s stock valued at $473,000 after buying an additional 27 shares in the last quarter. Armbruster Capital Management Inc. increased its position in Johnson & Johnson by 0.7% in the second quarter. Armbruster Capital Management Inc. now owns 4,438 shares of the company’s stock valued at $538,000 after buying an additional 30 shares in the last quarter. Finally, Amarillo National Bank increased its position in Johnson & Johnson by 0.6% in the second quarter. Amarillo National Bank now owns 5,496 shares of the company’s stock valued at $667,000 after buying an additional 35 shares in the last quarter. 65.67% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>